Clementia Pharmaceuticals, Inc.

Ipsen SA has hit the acquisition trail again to snap up rare disease Albireo Ltd. in a near $1bn deal that should help soften the recent blow of the US Food and Drug Administration's rejection of t

Three candidates for US FDA approval are using real-world evidence as part of the efficacy argument, illustrating some of the most common ways to RWE in applications. In keeping with FDA’s history of

The perception of Ipsen SA as a conservative business has been turned on its head since David Loew took over as CEO in July 2020, with the French company becoming a flagbearer for mid-sized pharma b

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo